International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

10/519518 DT01 Rec'd PCT/PTC 2.3 DEC 2084

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-32. (Canceled)

- 33. (New) A metal electrode comprising a surface at which an oxidative drug-metabolizing enzyme (DME) is immobilized to allow efficient transfer of electrons from the electrode to a catalytic site within the DME.
- 34. (New) An electrode according to claim 33, wherein the DME is immobilized to the surface of the electrode by means of a linker.
- 35. (New) An electrode according to either claim 33 or 34, wherein the DME is covalently immobilized to the surface of the electrode.
- 36. (New) An electrode according to either claim 33 or 34, wherein the DME is non-covalently immobilized to the surface of the electrode.
- 37. (New) An electrode according to claim 33, wherein the surface of the electrode is modified by covalent or non covalent addition of chemical groups.
- 38. (New) An electrode according to claim 37, wherein the electrode is a gold electrode and the chemical groups are organothiolate compounds.

2

International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

39. (New) An electrode according to either claim 33 or 34, wherein the electrode surface is coated with a mechanically and chemically stable polymer gel having high ionic conductivity, and the DME is trapped within the polymer gel.

- 40. (New) An electrode according to claim 39, wherein the polymer gel comprises polymers having a high proportion of carboxylic acid groups and the DME has positively-charged surface residues.
- 41. (New) An electrode according to claim 39, wherein the polymer gel comprises polymers having a high proportion of amine groups and the DME has negative charges at the surface.
- 42. (New) An electrode according to claim 39, wherein the polymer gel comprises polymers having a high proportion of aliphatic groups and the DME has a hydrophobic surface.
- 43. (New) An electrode according to either claim 33 or 34, wherein the DME is a cytochrome P450 (CYP) which is by means of a lipid membrane deposited on the surface of the electrode.
- 44. (New) An electrode according to claim 43, wherein the lipid membrane comprises long-chain fatty acids or lipids.
- 45. (New) An electrode according to claim 34, wherein the linker comprises a delocalized electron system.
- 46. (New) An electrode according to claim 34 wherein the linker comprises a functional group that is selected from the group consisting of a hydroxyl


International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

group, an amide, an amine, a carboxylic acid group, an aromatic group, a cyclic group, a heterocyclic group, a thiophene, a nitrogen-containing heterocyclic group, a pyridine, a purine, a pyrimidine, an enol, an ether, a ketone, an aldehyde, a thiol, a thioether, a halo-, a nitro-, a phospho- and a sulphate group.

- 47. (New) An electrode according to claim 34 wherein the linker comprises a metallocene, a flavin, a quinone, or NADH.
- 48. (New) An electrode according to claim 47 wherein the linker comprises a metallocene that comprises a ferrocene.
- 49. (New) An electrode according to claim 48 wherein the ferrocene is a compound of the following formula:



wherein:

R1 is a functional group selected from the group consisting of a thiol, a thioether, an amide, an amine, a carboxylic acid, a heterocyclic group, a thiophene, a nitrogen containing heterocyclic group, a pyridine, a purine and a pyrimidine; and

R₂₋₁₀ are each independently a functional group selected from the group consisting of a hydroxyl group, an amide, an amine, a carboxylic acid group, an aromatic group, a cyclic group, a heterocyclic group, a thiophene, a nitrogen-containing

International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

heterocyclic group, a pyridine, a purine, a pyrimidine, an enol, an ether, a ketone, an aldehyde, a thiol, a thioether, a halo-, nitro-, phospho-, and a sulphate group.


- 50. (New) A metal electrode having a surface modified by covalent or non covalent addition of a chemical group to allow transfer of electrons from the electrode to a catalytic site within a solubilized DME at a rate that is at least as fast as a rate of consumption of electrons by the DME when metabolizing a candidate drug.
- 51. (New) An electrode according to claim 50 wherein the electrode is a gold electrode and the chemical group comprises an organothiolate compound having (i) an SH group which forms a bond to the surface of the electrode, and (ii) a functional group for interacting with the solubilized DME.
- 52. (New) An electrode according to claim 51 wherein the chemical group comprises a delocalized electron system.
- 53. (New) An electrode according to either claim 50 or 52, wherein the chemical group comprises a functional group selected from the group consisting of a hydroxyl group, an amide, an amine, a carboxylic acid group, an aromatic group, a cyclic group, a heterocyclic group, a thiophene, a nitrogen-containing heterocyclic group, a pyridine, a purine, a pyrimidine, an enol, an ether, a ketone, an aldehyde, a thiol, a thioether, a halo-, nitro-, phospho-, and a sulphate group.
- 54. (New) An electrode according to claim 50 wherein the chemical group comprises a metallocene, a flavin, a quinone, or NADH.
- 55. (New) An electrode according to claim 54 wherein the chemical group comprises a metallocene that comprises a ferrocene.

International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

56. (New) An electrode according to claim 55, wherein the ferrocene is a compound of the following formula:



wherein:

R1 is a functional group selected from the group consisting of a thiol, a thioether, an amide, an amine, a carboxylic acid, a heterocyclic group, a thiophene, a nitrogen containing heterocyclic group, a pyridine, a purine, and a pyrimidine; and

R₂₋₁₀ are each independently a functional group selected from the group consisting of a hydroxyl group, an amide, an amine, a carboxylic acid group, an aromatic group, a cyclic group, a heterocyclic group, a thiophene, a nitrogen-containing heterocyclic group, a pyridine, a purine, a pyrimidine, an enol, an ether, a ketone, an aldehyde, a thiol, a thioether, a halo-, nitro-, phospho-, and a sulphate group.

- 57. (New) An electrochemical reaction chamber comprising a first electrode according to the metal electrode of claim 33; and a second electrode.
- 58. (New) A device comprising a plurality of electrochemical reaction chambers according to claim 57, wherein the first electrode of each electrochemical reaction chamber comprises a different DME.

International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

59. (New) An electrochemical reaction chamber comprising a first electrode according to the metal electrode of claim 50; a second electrode; and a DME.

60. (New) A device comprising a plurality of electrochemical reaction chambers according to claim 59, wherein the first electrode of each electrochemical reaction chamber comprises a different DME.

61. (New) A method of determining metabolism of a drug by a drugmetabolizing enzyme, comprising:

providing (i) a candidate drug and (ii) a metal electrode that comprises a surface at which an oxidative drug-metabolizing enzyme (DME) is immobilized to allow efficient transfer of electrons from the electrode to a catalytic site within the DME, under conditions that allow transfer of electrons from the electrode to a catalytic site within the DME;

applying changing voltage to the electrode to supply the DME with electrons; and

measuring a rate of consumption of the electrons by the DME, and therefrom determining metabolism of the candidate drug by the DME.

62. (New) A method of determining metabolism of a drug by a drugmetabolizing enzyme, comprising:

providing a candidate drug in solution in an electrochemical reaction chamber, wherein the chamber comprises a metal electrode that comprises a surface at which an oxidative drug-metabolizing enzyme (DME) is immobilized to allow efficient transfer of electrons from the electrode to a catalytic site within the DME, under conditions that allow transfer of electrons from the electrode to a catalytic site within the DME;

applying changing voltage to the electrochemical reaction chamber; and

International Application No.: PCT/GB2003/002756

International Filing Date: June 27, 2003

Preliminary Amendment

measuring current flowing through the electrochemical reaction chamber, and therefrom determining metabolism of the candidate drug by the DME.

63. (New) A method of determining metabolism of a drug by a drugmetabolizing enzyme, comprising:

providing (i) a candidate drug and (ii) metal electrode having a surface modified by covalent or non covalent addition of chemical groups to allow transfer of electrons from the electrode to a catalytic site within a solubilized DME at a rate that is at least as fast as a rate of consumption of electrons by the DME when metabolizing a candidate drug;

applying changing voltage to the electrode to supply the DME with electrons; and

measuring a rate of consumption of the electrons by the DME, and therefrom determining metabolism of the candidate drug by the DME.

64. (New) A method of determining metabolism of a drug by a drugmetabolizing enzyme, comprising:

providing a candidate drug in solution in an electrochemical reaction chamber, wherein the chamber comprises a metal electrode having a surface modified by covalent or non covalent addition of chemical groups to allow transfer of electrons from the electrode to a catalytic site within a solubilized DME at a rate that is at least as fast as a rate of consumption of electrons by the DME when metabolizing a candidate drug;

applying changing voltage to the electrochemical reaction chamber; and measuring current flowing through the electrochemical reaction chamber, and therefrom determining metabolism of the candidate drug by the DME.